Spotlight On... UT Southwestern team creates new drug that could aid in vaccine development; GSK seeks to expand FluLaval indication; China FDA clears Sinovac to start producing EV71 vaccine; and more...

Researchers at the University of Texas Southwestern Medical Center have discovered a new drug that could help in vaccine development. It activates the innate immune system in a novel way, UT Southwestern said in a statement. "The drug we made appears safe, and boosts immunity in mice. Therefore, the drug, which is straightforward to synthesize and to couple to antigens that induce an immune response, may prove useful in the generation of vaccines," said Dr. Bruce Beutler, Director of UT Southwestern's Center for the Genetics of Host Defense. More

> GlaxoSmithKline ($GSK) filed a regulatory submission in the U.S. to expand the indication of its FluLaval Quadrivalent vaccine. Release

> The China FDA issued a GMP certificate to Sinovac ($SVA), clearing it to start producing a vaccine for EV71, which causes hand, foot and mouth disease. More

> Mymetics announced it will discontinue its RSV collaborative project in July. Release

And Finally... Drexel University researchers found that 75% of vaccine-related posts on Pinterest are negative toward vaccination. Release

Suggested Articles

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

As Merck and Pfizer race to market with next-gen vaccines, the companies are fighting in court over a trade secrets lawsuit from Merck.

After working with the government for years to advance a next-gen smallpox vaccine, Bavarian Nordic has finally scored its approval.